The Daily Buyout
$12MStrategic acquisitionHealthcare & Life Sciences

RedHill Buys Commercialization Rights to Ferring's Rebyota and Clenpiq

RedHill Biopharma acquired exclusive commercialization rights to Ferring's Rebyota and Clenpiq for a $12 million upfront payment plus milestones and royalties, funded by its $18 million Talicia divestiture.

Read the full coverage, free

We only link to sources you can read without a subscription. How we check.

More Healthcare & Life Sciences deals